J&J Opens San Francisco R&D Campus
Will feature drug discovery, gene and RNA therapy technology
Johnson & Johnson has opened its San Francisco Bay campus, a state-of-the-art research & development facility in the Bay Area, often known as global hub for innovation and entrepreneurship. The nearly 200,000 square-foot facility will be home to up to 400 employees, more than doubling the R&D presence of J&J in that area. The campus connects scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology.
The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies; novel treatments and approaches for retinal and infectious diseases; and advanced data science, including artificial intelligence and machine learning.
“Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop, and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science, and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” says James Merson, PhD, site head, San Francisco Bay campus and global therapeutic area head, infectious diseases, Janssen Research & Development, LLC.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.
